| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $11.7M | — | -10.0% |
| SG&A Expense | $3.9M | — | -2.0% |
| Operating Income | -$15.6M | — | +8.1% |
| Net Income | -$15.2M | -12.2% | +4.8% |
| EPS (Basic) | -$1.11 | — | +6.7% |
| EPS (Diluted) | -$1.11 | — | +6.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $192.1M | +225.3% | +98.7% |
| Current Assets | $197.5M | +224.6% | +101.2% |
| Total Assets | $198.7M | +219.9% | +98.9% |
| Current Liabilities | $14.3M | +142.0% | +63.1% |
| Total Liabilities | $14.3M | +141.7% | +55.3% |
| Stockholders' Equity | $184.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.9M | — | +7.6% |
| Capital Expenditures | $5K | — | -72.2% |
| Investing Cash Flow | -$5K | — | +72.2% |
| Financing Cash Flow | $146.0M | — | — |
| Free Cash Flow | -$12.9M | — | +7.7% |
| +103.4% |